Sermorelin and tesamorelin are both copies of growth hormone-releasing hormone, GHRH, built by two different routes. Sermorelin is the first 29 amino acids of the hormone. Tesamorelin is a stabilized version of the full 44 amino acid molecule. They act on the same receptor and aim at the same hormone, and what separates them is how much has been measured. Tesamorelin has pooled phase 3 trials with a CT scan as the endpoint. Sermorelin has a clinical record from earlier decades, a review and some pediatric work. This sermorelin vs tesamorelin comparison covers what each one is, what the studies found, and what a lab report should show. Everything below describes laboratory research.
TesamorelinSermorelin vs tesamorelin: what is the difference?
Sermorelin is GHRH(1-29), the first 29 amino acids of the hormone. Tesamorelin is GHRH(1-44), the full-length molecule, stabilized. Both reach the same GHRH receptor on the pituitary. The practical differences are length, stability and the research record. A longer, stabilized molecule leaves more room for synthesis errors, so the identity line on a certificate matters, and a shorter one carries less of that risk.
Sermorelin vs tesamorelin side by side
The table holds what the literature supports. Tesamorelin’s size, price and batch data are pulled live from the product and certificate pages, and the sermorelin cells say what to ask a seller. Searched as tesamorelin vs sermorelin, the table is the same.
| Sermorelin | Tesamorelin | |
|---|---|---|
| What it is | GHRH(1-29), the first 29 amino acids | A stabilized GHRH(1-44), the full-length analog |
| Receptor | GHRH receptor | GHRH receptor |
| Best-known human record | A 2006 review in adult growth hormone insufficiency, plus 1990s pediatric work | Two pooled phase 3 trials, 806 patients |
| Endpoint measured | Growth and hormone responses | Visceral fat by CT scan |
| Size and price | Varies by seller | 10mg vial, $89.99 |
| Latest batch purity (HPLC) | Ask the seller for the batch report | 99.5% |
| Certificate | Ask the seller for the certificate | Tesamorelin COA |
What sermorelin is and what its research covers
Walker’s 2006 review in Clinical Interventions in Aging asks whether sermorelin offers a better approach to adult-onset growth hormone insufficiency, which sets it in a human endocrine context. The older pediatric literature includes a comparative study of growth hormone and GHRH(1-29)NH2 for stimulating growth in children with growth hormone deficiency and another comparing growth responses to GHRH(1-29)NH2 and growth hormone, both in Acta Paediatrica Supplement in 1993. That record concerns specific clinical conditions and doesn’t extend to the research settings tesamorelin is studied in. The sermorelin peptide guide goes through the compound.
What tesamorelin is and what its research covers
Falutz and colleagues in the Journal of Clinical Endocrinology and Metabolism pooled two phase 3 studies in 806 HIV patients on antiretroviral therapy with excess abdominal fat. CT-measured visceral fat fell against placebo at 26 weeks, with a treatment effect of 15.4 percent, and subcutaneous fat didn’t change meaningfully. Dhillon’s review in Drugs describes the analog as indicated for reducing excess abdominal fat in HIV-associated lipodystrophy, and notes that visceral fat re-accumulated when treatment stopped. Stanley and colleagues in Lancet HIV found a greater reduction in liver fat than placebo in 61 people with HIV and fatty liver disease. The tesamorelin peptide guide covers the compound in more detail.
How the two molecules differ
Length is the first difference: 29 amino acids against 44. Stability is the second. Native GHRH is short-lived, a problem Teichman’s CJC-1295 paper opens with, and each analog tackles it differently. Tesamorelin is described as stabilized, and the long-acting form of CJC-1295 binds albumin. Sermorelin keeps the shorter fragment and isn’t engineered for extended action. The result is two molecules that give the same signal with different footprints, and the research on one can’t be borrowed for the other.
What the tesamorelin research covers that the sermorelin research doesn’t
Tesamorelin’s trials used imaging endpoints in a defined patient population. Sermorelin’s literature is a mix of review and pediatric growth work from earlier decades. The two don’t overlap in design, population or outcome, so statements that tesamorelin is “more proven” are really statements about a trial program rather than about the molecule’s biology. The CJC-1295 and ipamorelin vs sermorelin and CJC-1295 and ipamorelin vs tesamorelin pages set both against the longer-acting and secretagogue compounds.
What a GHRH analog does and doesn’t do, per the research
Both compounds work upstream of growth hormone: they signal the pituitary to release its own hormone, so the output depends on the gland’s response. That’s the mechanistic case for the family over giving growth hormone directly, and the Ionescu pulsatility paper on CJC-1295 shows the idea in practice, with pulses preserved while baseline levels rose. It is also a limit. A GHRH analog raises a hormone, and a hormone level isn’t an outcome. The tesamorelin trials are valuable because they went on to measure fat on a CT scan, which is an outcome. Sermorelin’s record, as cited here, doesn’t include an equivalent endpoint, and a page that credits it with body-composition results is borrowing from a different compound.
Reading comparison pages on sermorelin and tesamorelin
Many pages on this pair come from clinics, and they tend to frame the compounds around goals such as vitality or recovery. Those words describe human outcomes that the cited papers don’t measure for sermorelin, and that the tesamorelin trials measured only for visceral fat in one population. A useful filter is the same one for any comparison: find the paper, then check which compound it studied, in whom, and with what endpoint. Where the answer is children with growth hormone deficiency, the claim is a pediatric claim, and where it is HIV patients and a CT scan, it is a fat claim in that group.
Sermorelin and tesamorelin in women’s research
The tesamorelin trials enrolled HIV patients, and the abstracts cited don’t break results out by sex. Growth hormone secretion differs by sex and across the menstrual cycle, so a result in one group can’t be assumed for another. The sermorelin material is a review and pediatric work. A woman framing her own research question will want sex-stratified data, which is thin for both. The tesamorelin for women page covers the compound with the deeper record.
What both peptides share, including the risks
Both signal through the GHRH receptor, so both depend on a functioning pituitary and the downstream hormone axis. The tesamorelin review reported injection-site reactions and events known from growth hormone therapy, such as joint pain, headache and swelling, and the Stanley trial reported more injection-site complaints than placebo. Trials of pharmaceutical products can’t be transferred to research-grade vials, and nothing here is guidance for any use.
What the sermorelin and tesamorelin studies can’t tell you
The tesamorelin trials enrolled people with HIV, so they say nothing about other populations or a laboratory model. The sermorelin sources are a review and older pediatric studies, and neither tests the two compounds against each other. Hormone release is a measurement, and the CT-scan endpoint in the tesamorelin trials is a body-composition outcome. Treat the comparison as two separate records, not a scoreboard.
Tesamorelin COA: what a lab report shows, and what to ask for on sermorelin
Every Healio Peptides batch is tested by an independent US laboratory before release, and the report is published before you order. This is the current tesamorelin batch.
| Tesamorelin | |
|---|---|
| Batch | HEALIO-TESA-2616 |
| Purity (HPLC) | 99.5% |
| Identity (ESI-MS) | Confirmed, conforms to the reference standard (5135.86) |
| Endotoxins (LAL) | Under 0.5 EU/mg (limit 5 EU/mg) |
The same four lines are what to ask for from any seller of sermorelin: purity by HPLC, identity by mass spectrometry, an endotoxin result, and a lot number that matches the vial. Tesamorelin at 44 amino acids and sermorelin at 29 both leave room for synthesis errors, so identity is the row to read closely. Reading a peptide certificate of analysis explains each row.
Tesamorelin price and format
Healio Peptides lists tesamorelin as a 10mg vial, lyophilized powder, at $89.99, which is $9.00 per mg. Sermorelin strengths and prices vary by seller, so compare cost per milligram. Reconstitution uses bacteriostatic water for sale, and the tesamorelin calculator turns vial strength and water volume into a concentration. How to reconstitute peptides covers the handling.
Where to buy tesamorelin for research
Whichever supplier you use, look for a published certificate before anything else, and match the lot number to the vial. Every Healio Peptides batch ships with a third-party report, and orders go out from the United States. The tesamorelin for sale page carries the certificate before you order, and the peptides for weight loss category shows the neighboring compounds.
Sermorelin vs tesamorelin: frequently asked questions
What is the difference between sermorelin and tesamorelin?
Sermorelin is the first 29 amino acids of GHRH. Tesamorelin is a stabilized version of the full 44 amino acid molecule. Both act on the same receptor.
What does tesamorelin do in the research?
In pooled phase 3 trials in HIV patients with excess abdominal fat, CT-measured visceral fat fell against placebo, and visceral fat re-accumulated when treatment stopped. It’s a result in one patient population.
Can tesamorelin and sermorelin be combined?
No paper cited here tests the two together, and they act on the same receptor, so they don’t add a second pathway the way a GHRH analog plus a secretagogue does.
Is tesamorelin a steroid?
No. It is a peptide analog of growth hormone-releasing hormone, not a steroid hormone.
Is tesamorelin FDA approved?
Nothing on this page is a statement about any product’s legal status or medical advice. A 2011 review describes a pharmaceutical tesamorelin as indicated for abdominal fat in HIV-associated lipodystrophy, which says nothing about research-grade vials. Healio Peptides sells tesamorelin strictly for laboratory research.
Do sermorelin and tesamorelin reviews tell me anything useful?
Reviews mix different products, forms and expectations, so they say little about any one vial. A batch certificate says more: it ties a purity and identity result to a lot number you can check.
More on growth hormone peptides
- Tesamorelin vs ipamorelin, two different receptors and two different records.
- CJC-1295 and ipamorelin vs sermorelin, one signal against two.
- Growth hormone peptides, the family explained.
Healio Peptides supplies research compounds for laboratory use only. They are not for human or veterinary use, have not been evaluated by the FDA, and nothing on this page is medical advice.